Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bff050e0ee69c0fc0c78b943b6067a098> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bff050e0ee69c0fc0c78b943b6067a098 NCIT_P378 "NCI" @default.
- Bff050e0ee69c0fc0c78b943b6067a098 type Axiom @default.
- Bff050e0ee69c0fc0c78b943b6067a098 annotatedProperty IAO_0000115 @default.
- Bff050e0ee69c0fc0c78b943b6067a098 annotatedSource NCIT_C77907 @default.
- Bff050e0ee69c0fc0c78b943b6067a098 annotatedTarget "A cancer vaccine in which autologous dendritic cells are transfected with patient-specific renal cell carcinoma (RCC) RNA and a synthetic, truncated human CD40 ligand (CD40L) RNA with potential immunostimulatory and antineoplastic activities. Individual RCC-specific RNA, encoding a unique repertoire of tumor-associated antigens (TAAs) (including telomerase reverse transcriptase, G250, and oncofetal antigen) is electroporated into autologous dendritic cells (DCs), transfected with synthetic RNA that encodes a truncated version of the T-cell protein CD40L; the transfected autologous DCs express and process both patient-specific RCC TAAs and the truncated CD40L protein. When reintroduced back to the patient, rocapuldencel-T may elicit a highly specific cytotoxic T-cell (CTL) response against RCC cells expressing the patient-specific RCC TAA repertoire. The signal cascade initiated by stimulation of the truncated, ectopically expressed co-stimulatory molecule CD40L results in the secretion of the inflammatory cytokine IL-12 downstream." @default.